Federal Register / Vol. 83, No. 1 / Tuesday, January 2, 2018 / Notices 135 

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1

Type of respondent FDA Form No.2 Number of 

respondents 

Number of 

responses per 

respondent 

Total annual 

responses 

Average 

burden per 

response 

(in hours) 

Total hours 

Cosmetics ........................... FDA 3613d ......................... 270 3 810 0.5 405 

Food .................................... FDA 3613e, 3613g, 3613l .. 881 5 4,405 0.5 2,203 

Total ............................. ............................................. ........................ ........................ ........................ ........................ 2,608 

1There are no capital costs or operating and maintenance costs associated with this collection of information. 

2All forms are submitted electronically via the Certificate Application Process (CAP). 

We have revised the currently 

approved burden estimate for the 

information collection to reflect the 

elimination of paper-based forms. 

Specifically, and based on our 

experience with the information 

collection, we have reduced the 

estimated time to prepare a submission 

from 1.5 hours to 0.5 hour. The previous 

estimate was based on the time 

necessary to prepare a paper 

submission, but all firms requesting 

export certificates now provide 

submissions electronically via CAP. We 

believe that the time to prepare an 

electronic submission is under 0.25 

hour, but are estimating 0.5 hour as a 

conservative approach to address all 

scenarios. We base our estimates of the 

total annual responses on our 

experience with certificate applications 

received in the past 3 fiscal years. 

We expect that most firms requesting 

export certificates in the next 3 years 

will choose to take advantage of the 

option of electronic submission via 

CAP. If a firm is unable to submit their 

information via CAP, they may contact 

CFSAN and request assistance. CFSAN 

will assist firms in entering their 

information into the electronic system 

so that the firm may receive their export 

certificates in a timely manner. Our 

burden estimates in Table 1 are based 

on the expectation of 100 percent 

participation in the electronic 

submission process. Providing the 

opportunity to submit the information 

in electronic format has reduced our 

previous estimates for the time to 

prepare each submission. 

Dated: December 26, 2017. 

Leslie Kux, 

Associate Commissioner for Policy. 

[FR Doc. 2017–28258 Filed 12–29–17; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Integrative, 

Functional and Cognitive Neuroscience 

Integrated Review Group; 

Neuroendocrinology, Neuroimmunology, 

Rhythms and Sleep Study Section. 

Date: February 1–2, 2018. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: New Orleans Marriott, 555 Canal 

Street, New Orleans, LA 70130. 

Contact Person: Michael Selmanoff, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5164, 

MSC 7844, Bethesda, MD 20892, 301–435– 

1119, mselmanoff@csr.nih.gov. 

Name of Committee: Biological Chemistry 

and Macromolecular Biophysics Integrated 

Review Group; Macromolecular Structure 

and Function A Study Section. 

Date: February 1–2, 2018. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Crowne Plaza Dallas Downtown, 

1015 Elm Street, Dallas, TX 75202. 

Contact Person: David R. Jollie, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4166, 

MSC 7806, Bethesda, MD 20892, (301)–408– 

9072, jollieda@csr.nih.gov. 

Name of Committee: Surgical Sciences, 

Biomedical Imaging and Bioengineering 

Integrated Review Group; Medical Imaging 

Study Section. 

Date: February 1–2, 2018. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Catamaran Resort, 3999 Mission 

Boulevard, San Diego, CA 92109. 

Contact Person: Xiang-Ning Li, MD, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5112, 

MSC 7854, Bethesda, MD 20892, 301–435– 

1744, lixiang@csr.nih.gov. 

Name of Committee: Population Sciences 

and Epidemiology Integrated Review Group; 

Social Sciences and Population Studies A 

Study Section. 

Date: February 1, 2018. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Marines’ Memorial Club & Hotel, 

609 Sutter Street, San Francisco, CA 94102. 

Contact Person: Suzanne Ryan, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3139, 

MSC 7770, Bethesda, MD 20892, (301) 435– 

1712, ryansj@csr.nih.gov. 

Name of Committee: Vascular and 

Hematology Integrated Review Group; 

Atherosclerosis and Inflammation of the 

Cardiovascular System Study Section. 

Date: February 1–2, 2018. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Sheraton Delfina Santa Monica 

Hotel, 530 West Pico Boulevard, Santa 

Monica, CA 90405. 

Contact Person: Natalia Komissarova, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5207, 

MSC 7846, Bethesda, MD 20892, 301–435– 

1206, komissar@mail.nih.gov. 

Name of Committee: Oncology 2— 

Translational Clinical Integrated Review 

Group; Developmental Therapeutics Study 

Section. 

Date: February 1–2, 2018. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Holiday Inn Bayside, 4875 North 

Harbor Drive, San Diego, CA 92106. 

Contact Person: Sharon K. Gubanich, 

Ph.D., Scientific Review Officer, Center for 


daltland on DSKBBV9HB2PROD with NOTICES
136 Federal Register / Vol. 83, No. 1 / Tuesday, January 2, 2018 / Notices 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6214, 

MSC 7804, Bethesda, MD 20892, (301) 408– 

9512, gubanics@csr.nih.gov. 

Name of Committee: Risk, Prevention and 

Health Behavior Integrated Review Group; 

Psychosocial Development, Risk and 

Prevention Study Section. 

Date: February 1–2, 2018. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Arlington, 1325 Wilson 

Boulevard, Arlington, VA 22209. 

Contact Person: Anna L. Riley, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3114, 

MSC 7759, Bethesda, MD 20892, 301–435– 

2889, rileyann@csr.nih.gov. 

Name of Committee: Bioengineering 

Sciences & Technologies Integrated Review 

Group; Biomaterials and Biointerfaces Study 

Section. 

Date: February 1–2, 2018. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Residence Inn Capital View, 2850 

South Potomac Avenue, Arlington, VA 

22202. 

Contact Person: Joseph D. Mosca, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5158, 

MSC 7808, Bethesda, MD 20892, (301) 408– 

9465, moscajos@csr.nih.gov. 

Name of Committee: Population Sciences 

and Epidemiology Integrated Review Group; 

Kidney, Nutrition, Obesity and Diabetes 

Study Section. 

Date: February 1–2, 2018. 

Time: 8:30 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Marriott Wardman Park Washington 

DC Hotel, 2660 Woodley Road NW, 

Washington, DC 20008. 

Contact Person: Fungai Chanetsa, MPH, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3135, 

MSC 7770, Bethesda, MD 20892, 301–408– 

9436, fungai.chanetsa@nih.hhs.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: December 26, 2017. 

Natasha M. Copeland, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–28226 Filed 12–29–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Current List of HHS-Certified 

Laboratories and Instrumented Initial 

Testing Facilities Which Meet Minimum 

Standards To Engage in Urine Drug 

Testing for Federal Agencies 

AGENCY: Substance Abuse and Mental 

Health Services Administration, HHS. 

ACTION: Notice. 

SUMMARY: The Department of Health and 

Human Services (HHS) notifies federal 

agencies of the laboratories and 

Instrumented Initial Testing Facilities 

(IITF) currently certified to meet the 

standards of the Mandatory Guidelines 

for Federal Workplace Drug Testing 

Programs (Mandatory Guidelines). 

A notice listing all currently HHScertified laboratories and IITFs is 

published in the Federal Register 

during the first week of each month. If 

any laboratory or IITF certification is 

suspended or revoked, the laboratory or 

IITF will be omitted from subsequent 

lists until such time as it is restored to 

full certification under the Mandatory 

Guidelines. 

If any laboratory or IITF has 

withdrawn from the HHS National 

Laboratory Certification Program (NLCP) 

during the past month, it will be listed 

at the end and will be omitted from the 

monthly listing thereafter. 

This notice is also available on the 

internet at http://www.samhsa.gov/ 

workplace. 

FOR FURTHER INFORMATION CONTACT: 

Giselle Hersh, Division of Workplace 

Programs, SAMHSA/CSAP, 5600 

Fishers Lane, Room 16N03A, Rockville, 

Maryland 20857; 240–276–2600 (voice). 

SUPPLEMENTARY INFORMATION: The 

Department of Health and Human 

Services (HHS) notifies federal agencies 

of the laboratories and Instrumented 

Initial Testing Facilities (IITF) currently 

certified to meet the standards of the 

Mandatory Guidelines for Federal 

Workplace Drug Testing Programs 

(Mandatory Guidelines). The Mandatory 

Guidelines were first published in the 

Federal Register on April 11, 1988 (53 

FR 11970), and subsequently revised in 

the Federal Register on June 9, 1994 (59 

FR 29908); September 30, 1997 (62 FR 

51118); April 13, 2004 (69 FR 19644); 

November 25, 2008 (73 FR 71858); 

December 10, 2008 (73 FR 75122); April 

30, 2010 (75 FR 22809); and on January 

23, 2017 (82 FR 7920). 

The Mandatory Guidelines were 

initially developed in accordance with 

Executive Order 12564 and section 503 

of Public Law 100–71. The ‘‘Mandatory 

Guidelines for Federal Workplace Drug 

Testing Programs,’’ as amended in the 

revisions listed above, requires strict 

standards that laboratories and IITFs 

must meet in order to conduct drug and 

specimen validity tests on urine 

specimens for federal agencies. 

To become certified, an applicant 

laboratory or IITF must undergo three 

rounds of performance testing plus an 

on-site inspection. To maintain that 

certification, a laboratory or IITF must 

participate in a quarterly performance 

testing program plus undergo periodic, 

on-site inspections. 

Laboratories and IITFs in the 

applicant stage of certification are not to 

be considered as meeting the minimum 

requirements described in the HHS 

Mandatory Guidelines. A HHS-certified 

laboratory or IITF must have its letter of 

certification from HHS/SAMHSA 

(formerly: HHS/NIDA), which attests 

that it has met minimum standards. 

In accordance with the Mandatory 

Guidelines dated January 23, 2017 (82 

FR 7920), the following HHS-certified 

laboratories and IITFs meet the 

minimum standards to conduct drug 

and specimen validity tests on urine 

specimens: 

HHS-Certified Instrumented Initial 

Testing Facilities 

Dynacare, 6628 50th Street NW, 

Edmonton, AB Canada T6B 2N7, 780– 

784–1190 (Formerly: GammaDynacare Medical Laboratories) 

HHS-Certified Laboratories 

ACM Medical Laboratory, Inc., 160 

Elmgrove Park, Rochester, NY 14624, 

844–486–9226 

Alere Toxicology Services, 1111 Newton 

St., Gretna, LA 70053, 504–361–8989/ 

800–433–3823 (Formerly: Kroll 

Laboratory Specialists, Inc., 

Laboratory Specialists, Inc.) 

Alere Toxicology Services, 450 

Southlake Blvd., Richmond, VA 

23236, 804–378–9130 (Formerly: 

Kroll Laboratory Specialists, Inc., 

Scientific Testing Laboratories, Inc.; 

Kroll Scientific Testing Laboratories, 

Inc.) 

Baptist Medical Center-Toxicology 

Laboratory, 11401 I–30, Little Rock, 

AR 72209–7056, 501–202–2783 

(Formerly: Forensic Toxicology 

Laboratory Baptist Medical Center) 

Clinical Reference Laboratory, Inc., 8433 

Quivira Road, Lenexa, KS 66215– 

2802, 800–445–6917 

DrugScan, Inc., 200 Precision Road, 

Suite 200, Horsham, PA 19044, 800– 

235–4890 


daltland on DSKBBV9HB2PROD with NOTICES